Physician profile
Beth Zimmer
NPI 1548221823
$324.50
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $311 · 2022: $13.57.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $113.63 | 2019 | |
| Janssen Pharmaceuticals, INC | $36.39 | 2019 | |
| Lilly USA, LLC | $31.26 | 2019 | |
| Ironshore Pharmaceuticals INC. | $19.18 | 2019 | |
| Novartis Pharmaceuticals Corporation | $16.87 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.37 | 2019 | |
| Allergan, INC. | $14.84 | 2019 | |
| Novo Nordisk INC | $14.26 | 2019 | |
| Dexcom, INC. | $13.57 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.77 | 2019 | |
| Pfizer INC. | $12.49 | 2019 | |
| Glaxosmithkline, LLC. | $11.63 | 2019 | |
| Amgen INC. | $11.24 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beth Zimmer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.